<DOC>
	<DOCNO>NCT02008110</DOCNO>
	<brief_summary>Preliminary data suggest potential role monitor up-titrate pharmacological therapy plasma level antigen carbohydrate 125 ( CA125 ) follow admission acute heart failure ( AHF ) . This study evaluate effect CA125-guided management strategy versus standard therapy composite endpoint 1-year all-cause mortality readmission AHF patient recently discharge AHF .</brief_summary>
	<brief_title>Carbohydrate Antigen 125-guided Therapy Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Age 18 year old . At least 1 admission AHF , last 180 day . Demonstrates functional New York Heart Association status Class ≥II moment enrollment . Objective evidence , either index admission least 180 day enrollment , structural functional abnormality heart rest , define : N terminalprobrain natriuretic peptide &gt; 1000 pg/ml brain natriuretic peptide &gt; 100 pg/ml echocardiographic abnormality congruent HF diagnosis : systolic leave ventricular dysfunction ( LVEF &lt; 50 % ) ; leave ventricular hypertrophy ( define leave ventricular septum leave ventricular posterior wall thickness ≥12 millimeter leave ventricular mass index &gt; 104 g/m2 woman 116 g/m2 men ) ; Ee ` &gt; 15 significant valvular heart disease ( moderatesevere ) . A plasma CA125 value &gt; 35 U/ml recent test evaluation ( least 30 day enrollment , preferably assess hospital discharge ) . Patient must capable understand sign informed consent form . Life expectancy &lt; 12 month due disease different HF . Having undergone cardiac transplantation , coronary revascularization procedure ( percutaneous coronary intervention and/or coronary artery bypass graft ) cardiac valve replacement past 3 month . Angina pectoris high class II ( Canadian Cardiovascular Society Classification ) . Pregnancy moment enrollment . Valvular heart disease already schedule surgical intervention . Severe chronic obstructive and/or restrictive pulmonary disease , require continuous oxygen administration . Serum creatinine level &gt; 3 mg/dl chronic renal insufficiency dialysis treatment . Patients receive resynchronization therapy index admission . Significant concurrent medical disease include cancer history cancer within 5 year enter screening period , endometriosis , cirrhosis , acute coronary syndrome within 6 month , uncontrolled hypertension , history human immunodeficiency virus ( HIV ) infection , significant active infection . Participating another randomize study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Biomarker guided-therapy</keyword>
	<keyword>Carbohydrate antigen 125</keyword>
	<keyword>Clinical outcome .</keyword>
</DOC>